IBBR Publications

Found 24 results
Filters: Keyword is Neutralization Tests  [Clear All Filters]
2018
S Hasan S, Sun C, Kim AS, Watanabe Y, Chen C-L, Klose T, Buda G, Crispin M, Diamond MS, Klimstra WB, et al. Cryo-EM Structures of Eastern Equine Encephalitis Virus Reveal Mechanisms of Virus Disassembly and Antibody Neutralization. Cell Rep. 2018 ;25(11):3136-3147.e5.
2014
Georgiev IS, Rudicell RS, Saunders KO, Shi W, Kirys T, McKee K, O'Dell S, Chuang G-Y, Yang Z-Y, Ofek GA, et al. Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline. J Immunol. 2014 ;192(3):1100-6.
Correia BE, Bates JT, Loomis RJ, Baneyx G, Carrico C, Jardine JG, Rupert P, Correnti C, Kalyuzhniy O, Vittal V, et al. Proof of principle for epitope-focused vaccine design. Nature. 2014 ;507(7491):201-6.
Ofek GA, Zirkle B, Yang Y, Zhu Z, McKee K, Zhang B, Chuang G-Y, Georgiev IS, O'Dell S, Doria-Rose N, et al. Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6. J Virol. 2014 ;88(5):2426-41.
Tran K, Poulsen C, Guenaga J, de Val N, Alda Nde Val, Wilson R, Sundling C, Li Y, Stanfield RL, Wilson IA, et al. Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign. Proc Natl Acad Sci U S A. 2014 ;111(7):E738-47.
2013
Georgiev IS, Doria-Rose NA, Zhou T, Kwon YDo, Staupe RP, Moquin S, Chuang G-Y, Louder MK, Schmidt SD, Altae-Tran HR, et al. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science. 2013 ;340(6133):751-6.
Zhu J, Ofek GA, Yang Y, Zhang B, Louder MK, Lu G, McKee K, Pancera M, Skinner J, Zhang Z, et al. Mining the antibodyome for HIV-1-neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains. Proc Natl Acad Sci U S A. 2013 ;110(16):6470-5.
2012
Zhang M-Y, Yuan T, Li J, Borges ARosa, Watkins JD, Guenaga J, Yang Z, Wang Y, Wilson R, Li Y, et al. Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41. PLoS One. 2012 ;7(9):e44241.
2011
Kim M, Sun Z-YJ, Rand KD, Shi X, Song L, Cheng Y, Fahmy AF, Majumdar S, Ofek GA, Yang Y, et al. Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization. Nat Struct Mol Biol. 2011 ;18(11):1235-43.
S Dennison M, Sutherland LL, Jaeger FH, Anasti KM, Parks R, Stewart S, Bowman C, Xia S-M, Zhang R, Shen X, et al. Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41. PLoS One. 2011 ;6(11):e27824.
Li Y, O'Dell S, Walker LM, Wu X, Guenaga J, Feng Y, Schmidt SD, McKee K, Louder MK, Ledgerwood JE, et al. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol. 2011 ;85(17):8954-67.
2010
Wu X, Yang Z-Y, Li Y, Hogerkorp C-M, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010 ;329(5993):856-61.
Ofek GA, McKee K, Yang Y, Yang Z-Y, Skinner J, F Guenaga J, Wyatt R, Zwick MB, Nabel GJ, Mascola JR, et al. Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region. J Virol. 2010 ;84(6):2955-62.
2009
Li Y, Svehla K, Louder MK, Wycuff D, Phogat S, Tang M, Migueles SA, Wu X, Phogat A, Shaw GM, et al. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol. 2009 ;83(2):1045-59.
Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, Ott RG, Anthony RM, Zebroski H, Hurley A, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature. 2009 ;458(7238):636-40.
2008
Selvarajah S, Puffer BA, Lee F-H, Zhu P, Li Y, Wyatt R, Roux KH, Doms RW, Burton DR. Focused dampening of antibody response to the immunodominant variable loops by engineered soluble gp140. AIDS Res Hum Retroviruses. 2008 ;24(2):301-14.
2007
Li Y, Migueles SA, Welcher B, Svehla K, Phogat A, Louder MK, Wu X, Shaw GM, Connors M, Wyatt RT, et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med. 2007 ;13(9):1032-4.
Dey B, Pancera M, Svehla K, Shu Y, Xiang S-H, Vainshtein J, Li Y, Sodroski J, Kwong PD, Mascola JR, et al. Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity. J Virol. 2007 ;81(11):5579-93.
Sponseller BA, Sparks WO, Wannemuehler Y, Li Y, Antons AK, J Oaks L, Carpenter S. Immune selection of equine infectious anemia virus env variants during the long-term inapparent stage of disease. Virology. 2007 ;363(1):156-65.
Mutwiri G, Benjamin P, Soita H, Townsend H, Yost R, Roberts B, Andrianov AK, Babiuk LA. Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens. Vaccine. 2007 ;25(7):1204-13.
2006
Li Y, Svehla K, Mathy NL, Voss G, Mascola JR, Wyatt R. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J Virol. 2006 ;80(3):1414-26.
2005
Grundner C, Li Y, Louder M, Mascola J, Yang X, Sodroski J, Wyatt R. Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins. Virology. 2005 ;331(1):33-46.
Forsell MNE, Li Y, Sundbäck M, Svehla K, Liljeström P, Mascola JR, Wyatt R, Hedestam GBKarlsson. Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus. J Virol. 2005 ;79(17):10902-14.
2004
Ofek GA, Tang M, Sambor A, Katinger H, Mascola JR, Wyatt R, Kwong PD. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol. 2004 ;78(19):10724-37.